Strides Pharma arm gets EU-GMP certification for 2 facilities from Hungary

Strides Pharma Science on Thursday said its subsidiary has received EU-GMP certification for two of its manufacturing facilities from Hungary's National Institute of Pharmacy and Nutrition

pharma
Press Trust of India New Delhi
2 min read Last Updated : Jun 16 2022 | 11:07 AM IST

Strides Pharma Science on Thursday said its subsidiary has received EU-GMP certification for two of its manufacturing facilities from Hungary's National Institute of Pharmacy and Nutrition.

Stelis Biopharma, an emerging biopharmaceutical and vaccine Contract Development and Manufacturing Organisation (CDMO) and the biologics arm of Strides Pharma, has received the European Union Goods Manufacturing Practices (EU-GMP) certification for the two manufacturing plants.

"The approval from EU-GMP is a significant first step in our journey to build a global biologics CDMO platform that offers end-to-end solutions across the modalities," company founder Arun Kumar said in a statement.

The facilities are designed to meet global regulatory standards, and as the other global inspections also come through, the company would have all the necessary approvals to cater to global players, he added.

"The last few quarters for our CDMO business have been eventful as we concluded various major contracts. These contracts have added new service revenues to our business and resulted in a commercial sales value of over USD 85 million in the peak year," Kumar stated.

Stelis' flagship facility (Unit 2, Bengaluru, India) is an integrated manufacturing set-up that leverages microbial and mammalian platforms for developing and commercialisng biologics and biosimilars in multiple fill-finish formats, including cartridges, devices, pre-filled syringes, liquid, and lyophilized vials.

Besides, its small-scale cGMP manufacturing facility (Unit 1, Bengaluru, India) is designed to support small-scale commercial and cGMP clinical trial material generation and initial technology transfer activities across multiple modalities.

With over USD 300 million in investments, Stelis has built a robust CDMO platform that offers one of APAC's largest drug substance capacities with over 48,000 litre across various modalities and drug product capacities exceeding 400 million units per annum.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Strides PharmaHungary

First Published: Jun 16 2022 | 11:07 AM IST

Next Story